LOS ANGELES, Sept. 8, 2004 (PRIMEZONE) -- HeartSTAT Technology, Inc. (Pink Sheets:HSTA), today announced that Mr. Patrick A. Maley was recently formally elected as a member of the Board of Directors.
Mr. Maley is Chief Operating Officer of Biowave, Inc. of Norwalk CT, and has served as management consultant to other medical device companies. Previously he was Vice President Sales and Marketing of Maritech, Inc., a supplier of cancer detection systems; Zoll Medical, a supplier of heart defibrillator devices; and at Boston Scientific Corporation. Mr. Maley received his BA and MBA degrees at the University of California.
Commenting on the announcement, Ted Russell, Chairman and Chief Executive Officer of HeartSTAT stated, "Pat Maley is a well rounded medical device company manager with a proven reputation for understanding product market strategy and introduction requirements. Mr. Maley has had an active interest in our senior operating and marketing management and he brings key experience to our Board to help guide our preparation for product marketing. We welcome him to the Board and are confident that he can add significant value to our goal to achieve market leadership in patient monitoring and cardiovascular disease management."
About HeartSTAT Technology, Inc.
HeartSTAT is bringing to market the first practical system for monitoring blood flow perfusion (blood oxygen transport) and heart dynamics, which have been impracticalities until now.
Initially, the new HeartSTAT technology is intended for early interventional prevention of septic shock and other conditions that kill 300,000 patients in U.S. hospitals annually, a mortality that is almost as large as cancer. The system is for revealing vital patient problems that alter blood flow while BP does not change, to enable providing earlier and more specific intervention than is presently possible. This system can also provide real time monitoring of heart loads and cardiovascular biophysics, which may later open up a large Internet-based physician market for managing cardiovascular disease, drug interaction, heart attacks and heart failure.
More information is available at www.HeartSTAT.com.
Statements in this release are made pursuant to the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risk and uncertainties including, without limitation, continued acceptance of the Company's services, increased levels of competition for the Company and dependence on the performance of the Management of the Company.